Objectives: To prospectively estimate the association of preconception antiphospholipid antibodies (aPL) with subsequent pregnancy loss using a cohort design. aPL have been associated with recurrent early pregnancy loss (EPL) prior to 10 weeks in previous case-control studies. Prospective ascertainment of pregnancy loss is challenging, as most women do not seek care prior to EPL. Methods: Secondary analysis of the Effects of Aspirin in Gestation and Reproduction trial of preconception low-dose aspirin. Preconception anticardiolipin (aCL) and anti-b2-glycoprotein-I (a-b2-I) were assessed in 1208 women with one or two prior pregnancy losses and no more than two prior live births. Comparison cohorts were defined by positive aPL (þaPL) or negative aPL (-aPL) status. All women were followed for six menstrual cycles while trying to conceive; if successful, they underwent an ultrasound at 6-7 weeks' gestation. EPL was defined as loss prior to 10 weeks' gestation; embryonic loss was loss after visualization of an embryo but prior to 10 weeks; clinical loss was any loss after visualization of an embryo (with or without fetal cardiac activity detected). Results: In total, 14/1208 (1%) tested positive for þaPL. 786/1208 (65%) women had positive human chorionic gonadotropin during the study period, of which 9/786 (1%) had þaPL. Of the 786 pregnant women, 589 (75%) had live births and 24% had pregnancy losses. Women with þaPL experienced EPL at similar rates as women with -aPL, 44% vs 21% (aRR 2.4, 95% confidence interval (CI) 0.5-10.9). Embryonic loss was more common in women with þaCL IgM (aRR 4.8, 95% CI 1.0-23.0) and in women with two positive aPL. Clinical pregnancy loss was more common in women with positive a-b2-I IgM (50% vs 16.5%, aRR 3.7, 95% CI 1.3-10.8). Conclusion: Positive levels of aPL are rare in women with one or two prior pregnancy losses and are not clearly associated with an increased rate of subsequent loss. Clinical trial registration: The original source study was registered at ClinicalTrials.gov (#NCT00467363). Lupus (2018) 27, 1437-1445.
Introduction
Antiphospholipid antibodies (aPL) are linked to recurrent early pregnancy loss (EPL). Rates of aPL in women with recurrent EPL are 5-15%, compared to 2-6% in women without recurrent losses. [1] [2] [3] Furthermore, three consecutive, otherwise unexplained pregnancy losses prior to 10 weeks is one of the obstetric diagnostic criteria for antiphospholipid syndrome (APS). 4 The diagnosis of APS is made by the presence of both aPL and either obstetric criteria or thrombosis. Other clinical criteria include thrombosis, one or more unexplained fetal deaths >10 weeks, and one or more pregnancies delivered prior to 34 weeks' gestation for severe preeclampsia or placental insufficiency. 4 Although aPL have a well-established association with late pregnancy loss, 5 the relationship between EPL and aPL remains controversial. [6] [7] [8] The paucity of data regarding aPL and EPL is largely due to difficulty in ascertainment. EPL consists of preimplantation, preembryonic and embryonic losses, which many women experience prior to obtaining obstetric care. Accordingly, prospective cohort studies of women enrolled during pregnancy using clinic-or provider-based recruitment strategies fail to capture EPLs. Further, many studies evaluating the association of aPL and pregnancy loss combine EPL (<10 weeks) and later fetal losses. The majority of previous studies used a case-control design and are at high risk for selection biases due to truncation. 9 Only one prospective cohort study assessed EPL in association with aPL in women with previous pregnancy loss. They found that aPL were associated with a relatively higher embryonic loss rate (28 vs 13%), 10 but they did not assess the precise timing of loss or further subdivide losses into preimplantation, preembryonic or embryonic losses.
Given these knowledge gaps, our objective was to assess: (a) the frequency of aPL, and (b) the association between aPL and subsequent EPL, in a large, prospective cohort of women with one or two prior pregnancy losses enrolled prior to conception and followed closely through the preconception and early pregnancy time period.
Materials and methods

Study population
This secondary analysis is a prospective cohort study from the Effects of Aspirin in Gestation and Reproduction (EAGeR) randomized-controlled trial of preconception low-dose aspirin. The EAGeR trial (June 2007 through August 2012) included 1228 women aged 18-40 years who were attempting conception and had experienced one or two prior pregnancy losses, no more than two prior live births and no more than one elective termination or ectopic pregnancy, and had regular menstrual cycles (21-42 days in length). 11, 12 For this analysis, cohorts were defined by whether women tested aPL positive (þaPL) or negative (ÀaPL). All participating centers obtained Institutional Board approval for the primary study and informed consent was obtained from all participants. University of Utah Institutional Review Board application ''Effects of Aspirin in Gestation and Reproduction (EAGeR)'' (#00021732) was approved on 7 February 2008. Exclusion criteria included but were not limited to: clinical indication for use of anticoagulant therapy (including diagnosis of APS), chronic use of non-steroidal antiinflammatory drugs, major medical disorders, current use of contraception, and history of infertility or subfertility. Major medical disorders included diabetes, hypertension, systemic lupus erythematosus, untreated or active cancer, any history of prior cancer, liver disease, renal disease, rheumatoid arthritis, cardiac disease, pulmonary disease other than mild asthma, neurologic disease requiring medical treatment, hyperthyroidism, hypothyroidism, seizure disorder requiring the use of anticonvulsant medications, untreated vitamin B12 deficiency, severe anemia (hematocrit < 30%), hemophilia, gout and nasal polyps. Women were excluded if they lacked both intact fallopian tubes, both ovaries or a uterus; if they did not have regular menstrual cycles; or if they had more than one missed menses in the previous 12 months. Women were randomized to receive 81 mg aspirin (LDA) daily or placebo, starting after biospecimen collection at the enrollment visit, through up to six menstrual cycles of attempting pregnancy and until 36 weeks of pregnancy if pregnancy was achieved within six menstrual cycles. All participants received folic acid. For this analysis, all enrolled women with data on aPL measured at the enrollment visit were included (n ¼ 1208).
aPL assessment and classification aPL were assessed using samples obtained at the baseline visit, prior to conception or randomization to aspirin or placebo. Antibody levels were determined using DIASTAT Õ assays by Euro Diagnostica, specific for each aPL antibody, including anticardioplipin (aCL) IgM, aCL IgG, antib2-glycoprotein-I (a-b2-GP1) IgM and a-b2-GP1 IgG. Interassay coefficients of variance for positive controls were 7.8% for aCL IgM, 12.1% for aCL IgG, 7.9% for a-b2-GP1 IgM and 15% for a-b2-GP1 IgG. Lower limits of detection were 0.6 U/mL for aCL IgG, 0.9 U/mL for aCL IgM, 0.1 U/mL for a-b2-GP1 IgG and 0.1 U/mL for a-b2-GP1 IgM.
Antibody levels ! 40 U/mL were considered ''positive'' for aCL IgG and IgM, and antib2-GP1 IgG and IgM. Various definitions of þ aPL status were also defined: (a) any positive single antibody test, (b) two positive tests in any combination, (c) aCL IgG positive (d) aCL IgM positive, (e) a-b2-GP1-IgG positive or (f) ab2-GP1-IgM positive. Outcomes were compared between þaPL and -aPL) status using the various definitions. We also repeated analyses using a titer value of !20 U/mL as a cutoff for determining antibody positivity.
Outcome assessment
Pregnancies were identified using spot urine pregnancy tests at the clinical sites (Quidel Quickvue, Quidel Corporation, sensitive to 25 mIU/mL human chorionic gonadotropin (hCG)), as well as urine hCG testing that was performed later in the laboratory on the last 10 days of each woman's first and second cycle of study participation (using daily first-morning urine collected at home), and on spot urine samples collected at all visits scheduled to occur at a woman's next expected menses (day 2-4 of cycle). Free beta hCG was measured in these urine samples to enable more sensitive detection of very early pregnancy than possible with conventional urine pregnancy testing. Two laboratory assays for free beta hCG (catalog number 4221-16, Diagnostic Automation Inc.; catalog number RIS0011R, BioVendor) were sequentially employed to determine first ''potentially positive'' values (n ¼ 164), of which 21 were verified as positive tests for early hCG-detected pregnancy. 13 The primary outcome was early pregnancy EPL, defined as a loss prior to 10 weeks' gestation, and included preimplantation losses, preembryonic losses and embryonic losses.
Secondary outcomes were live birth, hCG pregnancy (all pregnancies detected by positive urine hCG), clinically confirmed pregnancy (via visualization of an embryo with ultrasound at approximately 6-7 weeks of gestation), clinical loss (defined as loss after ultrasound confirmation of pregnancy), embryonic loss, preterm birth prior to 37 weeks, preeclampsia (based on a diagnosis in the medical record using standard clinical and laboratory criteria) and small for gestational age at birth (SGA) (defined as birth weight at or below the 10th percentile for gestational age using the reference developed by Kramer et al.).
14 We included preeclampsia, SGA and preterm birth as outcomes because preterm birth due to preeclampsia or placental insufficiency is also part of APS. Embryonic losses were defined as losses occurring before 10 weeks' gestation with ultrasound visualization of an embryo at or prior to the loss. Preclinical loss was loss prior to clinically confirmed pregnancy via ultrasound visualization of an embryo. We acknowledge that these categories overlap, but because they have different diagnostic strategies, we found it useful to analyze all of them.
Statistical analysis
Demographic variables were compared between þaPL and ÀaPL groups using 2 tests and Students' t-tests, where appropriate. Pregnancy outcomes were reported by þaPL and ÀaPL status as frequencies and compared using Fisher's exact test. Women who withdrew prior to pregnancy outcome ascertainment were not included in this analysis. Outcomes were compared using the varying definitions for þaPL status. Risk ratios were estimated where possible using log binomial models with robust variance and were adjusted for the known confounders of number of previous losses, number of previous live births, maternal age, maternal body mass index (BMI) and allocation of aspirin/placebo per treatment group. Odds ratios were calculated in some cases when the number of cases was too small; in some scenarios, no models could be estimated due to insufficient cases. Outcomes of live birth, hCG pregnancy and clinical pregnancy were calculated among all women who completed follow-up, whereas pregnancy outcomes including loss, preterm, preeclampsia and SGA are restricted to women who became pregnant during the study period. In order to correctly estimate the association between aPL and pregnancy loss, preterm and preeclampsia, inverse probability weights were used to control for potential bias introduced by restricting the analysis to pregnant women. 15, 16 Analyses were conducted in SAS version 9.4 (SAS Institute, Cary, NC, USA).
Results
Of the 1228 women enrolled in the EAGeR trial, 1208 (98.4%) had available data on aPL. Of these women, 14 of 1208 (1.2%) tested positive for any aPL using a threshold of !40 U/mL; 786 (65.1%) of the 1208 women had a positive hCG test during the study period. Among those with a positive hCG test, 9 of 786 (1.1%) tested positive for any aPL (Figure 1 ). Demographic characteristics of women who tested positive for any aPL vs no aPL positivity are represented in Table 1 . There were no differences in characteristics between the þaPL and ÀaPL groups. The study population was predominantly white non-smokers. Mean age was 28.7 years and mean BMI was 26.3 kg/m 2 . There were no individuals with previously diagnosed APS.
Overall, 589 out of 786 (75%) women with positive hCG tests had live births and 186 (24%) had documented pregnancy losses. Four out of nine (44.4%) women with any þaPL experienced EPL, compared to 159 out of 777 (20.5%) women with ÀaPL (p ¼ 0.09) ( Table 2 ). After adjustment, there remained no difference in the rate of EPL between the þaPL and ÀaPL groups, though the estimate was imprecise due to few cases of aPL positivity (aRR 2.41, 95% confidence interval (CI) 0.53-10.89) ( Table 3) .
Two out of 9 (22.2%) women with any þaPL experienced embryonic pregnancy loss, compared to 70 out of 777 (9%) in ÀaPL (p ¼ 0.20). Embryonic loss was more common in women with þaCL IgM (aRR 4.82, 95% CI 1.01-22.98) compared with ÀaPL and in women with any two þaPL antibodies compared with -aPL. Clinical pregnancy loss was more common in women with þab2-GP1 IgM ! 40 U/mL (50% vs 16.5%, aRR 3.67, 95% CI 1.25-10.77).
SGA was more common in women with positive þab2-GP1 a-b2-GP1-IgM than with negative -ab2-GP1 a-b2-GP1-IgM (aRR 5.4, 95% CI 1. 16-25.16 ). None of the other secondary outcomes differed between aPL groups. Specifically, the rate of hCG pregnancy was similar between þaPL and ÀaPL groups (64.3% vs 65.1%, aRR 1.14, 95% CI 0.81-1.62) ( Table 3 ). The overall live birth rate (including women both with and without hCG pregnancy) was also similar between þaPL and ÀaPL women (35.7% vs 48.9%, aRR 0.84, 95% CI 0.42-1.66).
When analysis was repeated using 20 U/mL as the cutoff for þaPL, there were 36 women out of 1208 (3.0%) who tested þaPL. There was no difference in EPL or any other pregnancy loss rates among groups. Women with þaPL were less likely to have a positive hCG test than women with ÀaPL (47.2% vs 65.7%, p ¼ 0.03), but this difference did not persist after adjustment for maternal age and BMI (aRR 0.78, 95% CI 0.56-1.1). aCL IgG > 20 was associated with increased risk of preterm birth (50% vs 6.5%; aRR 5.58, 95% CI 1.25-24.83) and a diagnosis of preeclampsia (33% vs 7.6%; RR 6.32, 95% CI 1.56-25.6) relative to -aPL, although the RR for preeclampsia could not be adjusted as it only included one case.
Pregnancy outcomes for the nine women with þaPL who became pregnant during the study period are outlined in Table 4 . The four women with þaPL who experienced pregnancy loss had aPL titers as follows: (a) aCL IgM ¼ 44.42 U/mL, (b) ab2-GP1 IgM ¼ 122.52 U/mL, (c) ab2-GP1 IgM ¼ 79.42 U/mL and (d) ab2-GP1 IgG ¼ 82.07 U/mL, all well over the 40 U/mL cutoff.
Discussion
Using a prospectively observed cohort of 1208 women with one or two prior pregnancy losses, we found that the presence of any þaPL test in women was very uncommon, affecting only 14 women in total. We also found that the presence of a þaPL result was not associated with an increased risk of subsequent EPL. However, we acknowledge that this conclusion regarding the risk of subsequent loss is limited by small numbers. Our findings are consistent with the observational study of Chauler et al. in which women with an EPL in their first pregnancy were assessed for aPL, and their subsequent conceived pregnancy was evaluated. 10 The authors evaluated over 5700 women with a single prior miscarriage < 10 weeks gestation for aPL. For aCL and a-b2-GP1 immunoassays, positive results were those that exceeded the threshold of greater than the 99th percentile value of controls in their laboratory. Of 5742 women tested, 3.5% were positive at least once for any aPL. After excluding those with traditional risk factors for early miscarriage, 2.9% were repeatedly positive. Although we used a different immunoassay product and a cutoff of ! 40 U/mL in both the aCL and a-b2-GP1 assays, we believe our findings to be largely similar, though we found a lower rate of þaPL (1.2%), even with the inclusion of women with two prior pregnancy losses and later losses. Moreover, 3% of our patients were positive using a cutoff of ! 20 U/mL. Chauleur et al. also studied subsequent pregnancy outcomes in 142 þaPL cases (all available) compared to 142 ÀaPL controls. A second pregnancy loss occurred in 18 women without aPL (13%) and 44 women (31%) with aPL (odds ratio ¼ 3.09, 95% CI 1.68-5.7), rates of loss that were comparable to the 20.5 and 44.4% with subsequent EPL observed here in women without and with antibodies, respectively. Though we did not find as large an increase in odds of pregnancy loss with þaPL, despite our inclusion of women with two prior pregnancy losses and later losses, our findings are similar to those of Chauleur et al. Also, we would note that the CIs in both studies are fairly wide.
Previous case-control studies comparing aPL in women with and without recurrent pregnancy loss report associations between EPL and aPL inconsistently. 7 A meta-analysis demonstrated an association between aCL and EPL, but EPL was defined as < 13 instead of 10 weeks' gestation, and only two studies were included. 17 One case-control study compared 273 women with EPL, 74 women with recurrent IVF failure and 200 control women. In this study, EPL was defined as two or more losses prior to 10 weeks' gestation, excluding any ectopic pregnancies. Women with pregnancy losses beyond 10 weeks were excluded. This is important because 131 (17) >0.99 2 (50) 129 (17) 0.09 0 (0) 131 (17) >0.99
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their case phenotype was truly an EPL-only phenotype. In that study, women with recurrent EPL did not have an increased rate of aPL. Moreover, when the recurrent EPL group was narrowed to women with three or more EPLs (n ¼ 108), there was still no association with aPL. 18 It may be that any association between aPL and EPL is minimal and difficult to detect when EPL is strictly defined. Models for pregnancy loss, preterm birth, preeclampsia, and SGA were weighted using inverse probability weights to account for potential bias due to restricting to pregnant women. aCL: anticardiolipin antibodies; aRR: ; RR: risk ratio; EPL: early pregnancy loss; hCG: human chorionic gonadotropin; SGA: small gestational age at birth.
Additionally, it is exceedingly difficult to assess EPL, as most women do not seek care during early gestation. Our findings overcome this common shortfall in study designs because we enrolled women prior to conception with thorough prospective ascertainment (and timing) of pregnancy and loss, permitting accurate ascertainment and assessment of the timing of all pregnancy losses. We found a very low frequency of baseline aPL in this population (1.2%); much lower than the 5% reported in previous low-risk populations and the 15% reported in women with recurrent pregnancy loss. 7 In turn, this limited our power to detect small associations between aPL and EPL.
It is not clear why the rate of þaPL was so low in our cohort. We believe this is most likely due to using robust thresholds to define positive results for aPL and stringent criteria for EPL. Our findings may reflect a more accurate assessment of incidence in this population because of our rigorous definitions of positive results. Many older case-control studies used lower titers, multiples of the mean or multiples-of-the-median to define positive results. 7 Other studies include early fetal losses as well, as it can be difficult to assess whether loss was embryonic or fetal retrospectively. In addition, our cohort included women with one or two prior losses, as opposed to recurrent pregnancy loss. Many definitions of recurrent EPL require three consecutive losses, as do current criteria for APS. However, in practice, many practitioners are currently testing for aPL after only two losses, making our study cohort clinically relevant.
The generalizability of these results is limited by our population characteristics. Participants were generally healthy, non-Hispanic white, educated, affluent and thin compared to the general population. It is possible that aPL would be more common in a higher-risk population.
Another limitation was the lack of assessment of lupus anticoagulant (LA). There are limited data regarding the association between LA and EPL, perhaps because positive tests for LA are even less common than for aCL and ab2-GPI in an EPL population. 8, 19 Chauler et al. found that less than 10% of women with a prior pregnancy loss and þaPL results were positive for LA alone, suggesting we would miss very few þaPL cases in the population we studied due to not performing a test for LA. Also, while we acknowledge the association between LA and both thrombosis and second-and third-trimester obstetric complications in APS, 10, 20 a meta-analysis of 25 studies found no data available for association between LA and pregnancy loss prior to 13 weeks. 17 Additionally, one study evaluating women with recurrent pregnancy loss found no cases of LA presence in women who had recurrent EPL alone and did not meet other clinical criteria for APS. 19 Similarly, a study grouping women with all obstetric criteria for APS found no association between LA and recurrent EPL, or between aCL and recurrent aPL. 21 Thus, assessment of LA is unlikely to alter our results or increase power.
We were also limited by a single time point of assessment for aPL. Diagnostic confirmation of APS requires repeat confirmatory testing for aPL at least 12 weeks later. However, we were not, attempting to make a diagnosis of APS, as no women in this group met clinical criteria for APS.
We did not assess aneuploidy as a cause of pregnancy loss in this study. However, as previously reported, a karyotype or chromosomal microarray was performed on 82 of the clinical losses. Of these, 29/82 (35.4%) were abnormal. 13 Low-dose aspirin use was not associated with aneuploidy. For this analysis, we did not evaluate the association of þaPL and aneuploidy, as these results were only available for a small proportion of pregnancy losses.
A significant strength of this study is its prospective nature, with participants enrolled and evaluated prior to attempting conception. There was also very close follow-up to allow thorough detection of early conception and thus all early losses. This study design makes our rate of EPL very reliable for this population. Additionally, we collected full demographic variables on participants at baseline, prior to knowledge of aPL status. This allows for unbiased adjustment of our associations and better control for possible confounders.
In sum, we conclude that positive levels of aPL are quite rare in women with one or two EPLs. Thus, our data do not support testing such women for aPL. Moreover, it is not clear that a positive test is associated with an overall rate of subsequent pregnancy loss. Our study had an insufficient sample size to make definitive conclusions regarding the relationship between aPL and EPL. When deciding whether or not to utilize a clinical test, it is important to evaluate the test's utility. Wald et al. have published critical questions to consider when choosing to recommend a test. 22 These questions include costs, benefits and what therapy would follow a positive result. Currently, aPL testing for women with one or two previous losses does not meet these predefined criteria.
Similarly, we cannot make determinations about EPL as a criterion for APS. The issue deserves further study. Meanwhile, it is reasonable to consider women with aPL and late pregnancy loss and EPL as two different populations until these relationships are clarified.
